Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer

Toru Nakanishi, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Tsutomu Kawabe, Naozumi Hashimoto, Masakazu Okamoto, Kaoru Shimokata

研究成果: Article査読

35 被引用数 (Scopus)


Background: Ligands for CXCR3 chemokines [IFN-γ-inducible protein of 10 kD (IP-10/CXCL10), monokine induced by IFN-γ (Mig/CXCL9), IFN-inducible T cell α chemoattractant (I-TAC/CXCL11)] and those for CCR4 [macrophage-derived chemokine (MDC/CCL22), thymus- and activation-regulated chemokine (TARC/CCL17)] have been shown to play the central roles for T helper-cell recruitment into the tissues. To examine the role of these chemokines in tumor progression of lung cancer, we investigated their expression in human lung cancer tissues to determine the possible relationship between their expression and the prognosis of patients. Methods: Total RNA was prepared from lung cancer tissues of 40 patients (24 adenocarcinoma and 16 squamous cell carcinoma). We measured gene expression levels of chemokines (IP-10, Mig, I-TAC, MDC and TARC) by real-time quantitative RT-PCR. Results: Higher gene expression of MDC in lung cancer was significantly correlated with longer disease-free survival time and lower risk of recurrence after tumor resection. We could not find any significant relationship of IP-10, Mig, I-TAC and TARC gene expression with disease-free survival or lower risk of recurrence after surgery. Conclusions: These results suggest that increased gene expression of MDC in tumor tissues may be a predictive marker for improving the prognosis of lung cancer.

ジャーナルCancer Immunology, Immunotherapy
出版ステータスPublished - 11-2006

All Science Journal Classification (ASJC) codes

  • 免疫アレルギー学
  • 免疫学
  • 腫瘍学
  • 癌研究


「Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。